Olin
OLN NYSE Diversified Chemicals Financials FY2016βFY2025
Olin's revenue rose 3.7% to $6.8 billion in fiscal 2025. Its operating margin was 0.1%, down from 4.5% a year earlier. Free cash flow was $248 million, down 19.5%. It paid out $142 million in dividends and buybacks, 57% of free cash flow. The diluted share count fell 4.1%.
What Olin does
No business description yet.
- Legal name
- OLIN CORPORATION
- Fiscal year ends
- December 31, 2025
- Latest annual report
- β
- Accession Β· CIK
- 0000074303-26-000027
0000074303
Revenue and margins
Olin had $6.8B of revenue in fiscal 2025, up 3.7% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $248M in fiscal 2025, 3.7% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Olin returned $142M to shareholders in fiscal 2025, 57% of free cash flow. The diluted share count fell 4.1%.
Value Olin yourself
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets β the answer depends entirely on what you put in.
Discounted cash flow
Value per share
β
Adds net cash of β$2.7B and divides by 114.6M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Balance sheet
Cash, debt and the ratios that show how comfortably Olin can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $181M | $194M | $170M | $176M | $168M |
| Debt incl. finance leases | $2.8B | $2.6B | $2.7B | $2.9B | $2.8B |
| Net debt / EBITDA | 1.1x | 1.0x | 2.0x | 3.3x | 5.1x |
| Debt / equity | 1.1x | 1.0x | 1.2x | 1.4x | 1.6x |
| Interest coverage | 5.3x | 12.4x | 3.9x | 1.6x | 0.0x |
| Current ratio | 1.3x | 1.4x | 1.3x | 1.3x | 1.2x |
| Quick ratio | 0.8x | 0.8x | 0.7x | 0.8x | 0.7x |
| Total assets | $8.5B | $8.0B | $7.7B | $7.6B | $7.3B |
| Total liabilities | $5.9B | $5.5B | $5.4B | $5.5B | $5.5B |
| Shareholders' equity | $2.7B | $2.5B | $2.2B | $2.0B | $1.8B |
| Net debt (β = net cash) | $2.6B | $2.4B | $2.5B | $2.7B | $2.7B |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$2.5M
5 insiders
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | Deon CarterVP & President CAPV | Sold | 6,500 | $23.73 | $0.2M | Form 4 |
| Feb 24, 2026 | Angela M CastleVP & Chief Legal Officer | Sold | 2,379 | $24.25 | $0.1M | Form 4 |
| Feb 3, 2026 | Sumner R NicholeVP & Controller | Sold | 4,750 | $22.49 | $0.1M | Form 4 |
| Feb 3, 2026 | Todd A SlaterVP & CFO | Sold | 92,250 | $22.48 | $2.1M | Form 4 |
| Nov 26, 2025 | Teresa M VermillionVP & Treasurer | Sold | 4,500 | $20.86 | $0.1M | Form 4 |
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | 4 / 9 | 4 / 9 | 4 / 9 |
| Accruals ratio | β6.6% | β5.2% | β7.7% |
| Altman Z'' | 2.53 | 2.06 | 1.62 |
Similar companies
Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Olin OLN | $1.8B | 3.7% | 0.1% | 3.7% | 0.1% | β | 4 | |
| Chemours CC | $1.9B | 0.5% | β | 0.9% | β0.2% | β | 4 | Compare β |
| Cabot CBT | $3.9B | β7.0% | 16.7% | 10.5% | 15.9% | 12.9x | 6 | Compare β |
| Ashland Global ASH | $3.4B | β13.7% | β42.5% | 2.0% | β17.5% | 69.5x | 5 | Compare β |
| CF Industries CF | $18.6B | 19.3% | 32.5% | 25.4% | 20.6% | 9.0x | 8 | Compare β |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $5.6B | $6.3B | $6.9B | $6.1B | $5.8B | $8.9B | $9.4B | $6.8B | $6.5B | $6.8B |
| Gross profit | $606M | $714M | $1.1B | $671M | $383M | $2.3B | $2.2B | $1.2B | $738M | $502M |
| Operating income | $108M | $297M | $677M | $178M | β$747M | $1.9B | $1.8B | $712M | $297M | $5.3M |
| Interest expense | $192M | $217M | $243M | $243M | $293M | $348M | $144M | $181M | $185M | $188M |
| Pretax income | β$34.2M | $117M | $437M | β$36.9M | β$1.0B | $1.5B | $1.7B | $559M | $142M | β$161M |
| Income tax | β$30.3M | β$432M | $109M | β$25.6M | β$50.1M | $242M | $349M | $107M | $36.7M | β$60.0M |
| Net income | β$3.9M | $550M | $328M | β$11.3M | β$970M | $1.3B | $1.3B | $452M | $105M | β$101M |
| Diluted EPS | β$0.02 | $3.26 | $1.95 | β$0.07 | β$6.14 | $7.96 | $8.94 | $3.57 | $0.91 | β$0.88 |
| Diluted shares | 0.17B | 0.17B | 0.17B | 0.16B | 0.16B | 0.16B | 0.15B | 0.13B | 0.12B | 0.11B |
| Cash flow | ||||||||||
| Cash from operations | $603M | $649M | $908M | $617M | $433M | $1.7B | $1.9B | $974M | $503M | $474M |
| Capital expenditure | $278M | $294M | $385M | $386M | $299M | $201M | $237M | $236M | $195M | $226M |
| Free cash flow | $325M | $355M | $523M | $232M | $134M | $1.5B | $1.7B | $738M | $308M | $248M |
| Depreciation and amortization | $534M | $559M | $601M | $597M | $568M | $583M | $599M | $533M | $518M | $522M |
| Stock-based compensation | $7.5M | $9.1M | $12.0M | $10.7M | $13.6M | $8.3M | $14.1M | $18.6M | $17.1M | $20.7M |
| Acquisitions | $69.5M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $63.9M | $0.0M | $55.8M |
| Share buybacks | $0.0M | $0.0M | $50.0M | $146M | $0.0M | $252M | $1.4B | $711M | $300M | $50.5M |
| Dividends paid | $132M | $133M | $134M | $129M | $126M | $128M | $116M | $101M | $94.2M | $91.6M |
| Dividends and buybacks | $132M | $133M | $184M | $275M | $126M | $380M | $1.5B | $812M | $395M | $142M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $185M | $218M | $179M | $221M | $190M | $181M | $194M | $170M | $176M | $168M |
| Total debt | $3.6B | $3.6B | $3.2B | $3.3B | $3.9B | $2.8B | $2.6B | $2.7B | $2.9B | $2.8B |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $5.3M | $4.3M | $3.0M | $1.9M | $0.0M | $0.0M | $0.0M |
| Current assets | $1.5B | $1.7B | $1.7B | $1.7B | $1.7B | $2.2B | $2.2B | $2.0B | $2.1B | $2.0B |
| Current liabilities | $923M | $954M | $1.1B | $1.1B | $1.2B | $1.7B | $1.6B | $1.5B | $1.6B | $1.6B |
| Inventory | $630M | $683M | $711M | $696M | $675M | $868M | $942M | $859M | $824M | $785M |
| Property and equipment, net | $3.7B | $3.6B | $3.5B | $3.3B | $3.2B | $2.9B | $2.7B | $2.5B | $2.3B | $2.2B |
| Total assets | $8.8B | $9.2B | $9.0B | $9.2B | $8.3B | $8.5B | $8.0B | $7.7B | $7.6B | $7.3B |
| Total liabilities | $6.5B | $6.5B | $6.2B | $6.8B | $6.8B | $5.9B | $5.5B | $5.4B | $5.5B | $5.5B |
| Shareholders' equity | $2.3B | $2.8B | $2.8B | $2.4B | $1.5B | $2.7B | $2.5B | $2.2B | $2.0B | $1.8B |
| Margins | ||||||||||
| Gross margin | 10.9% | 11.4% | 16.2% | 11.0% | 6.7% | 25.8% | 23.3% | 17.1% | 11.3% | 7.4% |
| Operating margin | 1.9% | 4.7% | 9.8% | 2.9% | β13.0% | 20.8% | 19.0% | 10.4% | 4.5% | 0.1% |
| EBITDA margin | 11.6% | 13.7% | 18.4% | 12.7% | β3.1% | 27.3% | 25.4% | 18.2% | 12.5% | 7.8% |
| Net margin | β0.1% | 8.8% | 4.7% | β0.2% | β16.8% | 14.6% | 14.2% | 6.6% | 1.6% | β1.5% |
| FCF margin | 5.9% | 5.7% | 7.5% | 3.8% | 2.3% | 17.3% | 18.0% | 10.8% | 4.7% | 3.7% |
| Returns | ||||||||||
| Return on capital | 1.5% | 5.0% | 8.4% | 2.5% | β11.1% | 30.0% | 27.7% | 11.8% | 4.6% | 0.1% |
| Return on capital employed | 1.4% | 3.7% | 8.4% | 2.2% | β9.8% | 26.6% | 26.7% | 11.2% | 4.9% | 0.1% |
| Return on equity | β0.2% | 21.9% | 11.7% | β0.4% | β50.2% | 63.2% | 51.1% | 18.9% | 4.9% | β5.2% |
| Return on assets | β0.0% | 6.1% | 3.6% | β0.1% | β11.1% | 15.5% | 16.0% | 5.7% | 1.4% | β1.4% |
| Growth | ||||||||||
| Revenue growth | 94.5% | 12.9% | 10.8% | β12.0% | β5.8% | 54.8% | 5.2% | β27.1% | β4.3% | 3.7% |
| Net income growth | β | β | β40.3% | β103.5% | β | β | 2.3% | β65.9% | β76.8% | β196.3% |
| EPS growth | β | β | β40.2% | β103.6% | β | β | 12.3% | β60.1% | β74.5% | β196.7% |
| FCF growth | 277.3% | 9.0% | 47.4% | β55.7% | β42.1% | 1,048.7% | 9.4% | β56.2% | β58.3% | β19.5% |
| Share count change | 59.8% | 2.0% | β0.1% | β3.6% | β2.7% | 3.2% | β8.9% | β13.3% | β7.2% | β4.1% |
| Financial health | ||||||||||
| Net debt / EBITDA | 5.4x | 4.0x | 2.4x | 4.0x | β | 1.1x | 1.0x | 2.0x | 3.3x | 5.1x |
| Debt / equity | 1.6x | 1.3x | 1.1x | 1.4x | 2.7x | 1.1x | 1.0x | 1.2x | 1.4x | 1.6x |
| Interest coverage | 0.6x | 1.4x | 2.8x | 0.7x | β2.6x | 5.3x | 12.4x | 3.9x | 1.6x | 0.0x |
| Current ratio | 1.7x | 1.8x | 1.5x | 1.6x | 1.4x | 1.3x | 1.4x | 1.3x | 1.3x | 1.2x |
| Quick ratio | 1.0x | 1.1x | 0.9x | 0.9x | 0.9x | 0.8x | 0.8x | 0.7x | 0.8x | 0.7x |
| Capital allocation | ||||||||||
| Capex / revenue | 5.0% | 4.7% | 5.6% | 6.3% | 5.2% | 2.3% | 2.5% | 3.5% | 3.0% | 3.3% |
| Stock comp / revenue | 0.1% | 0.2% | 0.2% | 0.2% | 0.2% | 0.1% | 0.2% | 0.3% | 0.3% | 0.3% |
| Payouts / FCF | 40.6% | 37.5% | 35.1% | 118.8% | 94.2% | 24.7% | 87.1% | 110.0% | 128.0% | 57.3% |
| Quality scores | ||||||||||
| Piotroski F-score | 4.0 | 7.0 | 7.0 | 4.0 | 3.0 | 7.0 | 7.0 | 4.0 | 4.0 | 4.0 |
| Altman Z'' | 1.1 | 1.5 | 1.8 | 1.3 | β0.0 | 2.8 | 3.4 | 2.5 | 2.1 | 1.6 |
| Accruals ratio | β6.7% | β1.1% | β6.4% | β6.9% | β16.1% | β5.3% | β7.2% | β6.6% | β5.2% | β7.7% |
Source: SEC EDGAR XBRL filings (CIK 0000074303). Data updated October 13, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.